These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2870085)

  • 21. Ultra-short-acting beta-blockade: a comparison with conventional beta-blockade.
    Reilly CS; Wood M; Koshakji RP; Wood AJ
    Clin Pharmacol Ther; 1985 Nov; 38(5):579-85. PubMed ID: 2865029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.
    Turlapaty P; Laddu A; Murthy VS; Singh B; Lee R
    Am Heart J; 1987 Oct; 114(4 Pt 1):866-85. PubMed ID: 2889341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electrophysiologic, cardiohemodynamic and beta-blocking actions of a new ultra-short-acting beta-blocker, ONO-1101, assessed by the in vivo canine model in comparison with esmolol.
    Sugiyama A; Takahara A; Hashimoto K
    J Cardiovasc Pharmacol; 1999 Jul; 34(1):70-7. PubMed ID: 10413070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
    Barbier GH; Shettigar UR; Appunn DO
    Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 9. Nadolol: a new long-acting beta-adrenoceptor blocking drug.
    Frishman W
    Am Heart J; 1980 Jan; 99(1):124-8. PubMed ID: 6101295
    [No Abstract]   [Full Text] [Related]  

  • 26. Beta-blocking and hemodynamic effects of ASL-8052.
    Gorczynski RJ; Murthy VS; Hwang TF
    J Cardiovasc Pharmacol; 1984; 6(6):1548-59. PubMed ID: 6084788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basic pharmacology of esmolol.
    Gorczynski RJ
    Am J Cardiol; 1985 Oct; 56(11):3F-13F. PubMed ID: 2864846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of esmolol (ASL-8052: an ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias.
    Byrd RC; Sung RJ; Marks J; Parmley WW
    J Am Coll Cardiol; 1984 Feb; 3(2 Pt 1):394-9. PubMed ID: 6141193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias.
    Gray RJ; Bateman TM; Czer LS; Conklin CM; Matloff JM
    J Am Coll Cardiol; 1985 Jun; 5(6):1451-6. PubMed ID: 2860148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selectivity of the intrinsic sympathomimetic activity of the beta-adrenergic blocking drug bucindolol.
    Leff AR; Garrity ER; Munoz NM; Tallet J; Cavigelli M; Deitchman D; Rajfer SI
    J Cardiovasc Pharmacol; 1984; 6(5):859-66. PubMed ID: 6209492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular pharmacology of ASL-8052, an ultra-short acting beta blocker.
    Murthy VS; Hwang TF; Zagar ME; Vollmer RR; Schmidt DH
    Eur J Pharmacol; 1983 Oct; 94(1-2):43-51. PubMed ID: 6140172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vasomolol: an ultra short-acting and vasorelaxant vanilloid type beta 1-adrenoceptor antagonist.
    Lin YT; Wu BN; Wu JR; Lo YC; Chen LC; Chen IJ
    J Cardiovasc Pharmacol; 1996 Jul; 28(1):149-57. PubMed ID: 8797149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol.
    Haeusler G; Schliep HJ; Schelling P; Becker KH; Klockow M; Minck KO; Enenkel HJ; Schulze E; Bergmann R; Schmitges CJ
    J Cardiovasc Pharmacol; 1986; 8 Suppl 11():S2-15. PubMed ID: 2439793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Some cardiovascular effects of timolol a new beta-adrenergic blocking agent.
    Scriabine A; Torchiana ML; Stavorski JM; Ludden CT; Minsker DH; Stone CA
    Arch Int Pharmacodyn Ther; 1973 Sep; 205(1):76-93. PubMed ID: 4148410
    [No Abstract]   [Full Text] [Related]  

  • 35. Esmolol: effects on isoprenaline- and exercise-induced cardiovascular stimulation in conscious dogs.
    Fischer G; Grohs JG; Raberger G
    Can J Physiol Pharmacol; 1990 Oct; 68(10):1322-8. PubMed ID: 1981854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemodynamic effects of esmolol, an ultrashort-acting beta blocker.
    Askenazi J; MacCosbe PE; Hoff J; Turlapaty P; Hua TA; Laddu A
    J Clin Pharmacol; 1987 Aug; 27(8):567-73. PubMed ID: 2888793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular effects of single oral doses of the new beta-adrenoceptor blocking agents betaxolol (SL 75212) in healthy volunteers.
    Cadigan PJ; London DR; Pentecost BL; Bianchetti G; Gomeni R; Kilborn JR; Morselli PL
    Br J Clin Pharmacol; 1980 Jun; 9(6):569-75. PubMed ID: 6104498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man.
    Giudicelli JF; Chauvin M; Thuillez C; Richer C; Bianchetti G; Gomeni R; Morselli PL
    Br J Clin Pharmacol; 1980 Jul; 10(1):41-9. PubMed ID: 6104973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisoprolol: a new beta-adrenoceptor blocking drug.
    Prichard BN
    Eur Heart J; 1987 Dec; 8 Suppl M():121-9. PubMed ID: 2897295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamics and onset of action of esmolol in anesthetized dogs.
    Quon CY; Gorczynski RJ
    J Pharmacol Exp Ther; 1986 Jun; 237(3):912-8. PubMed ID: 2872328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.